UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine [Yahoo! Finance]
Onconetix, Inc. (ONCO)
Company Research
Source: Yahoo! Finance
vaccine for chlamydia, the most reported sexually transmitted disease, with funding from the National Institutes of Health. SAN ANTONIO May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine. Chlamydia is the most reported sexually transmitted disease and affects about 4 million people in the United States each year, according to the Centers for Disease Control and Prevention. And yet, while there are vaccines for other sexually transmitted infections including HPV, hepatitis A and hepatitis B, there is none for chlamydia. The infection often is left untreated due to the lack of specific symptoms. Untreated chlamydial infections can lead to severe complications including pelvic inflammatory disease, infertility and ectopic pregnancy. The UT Health San Antoni
Show less
Read more
Impact Snapshot
Event Time:
ONCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCO alerts
High impacting Onconetix, Inc. news events
Weekly update
A roundup of the hottest topics
ONCO
News
- Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director [Yahoo! Finance]Yahoo! Finance
- Immunovia Publishes Interim Report for January-March 2024 [Yahoo! Finance]Yahoo! Finance
- Immunovia Publishes Interim Report for January-March 2024 [Yahoo! Finance]Yahoo! Finance
- Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study [Yahoo! Finance]Yahoo! Finance
ONCO
Sec Filings
- 6/25/24 - Form PRER14A
- 6/25/24 - Form S-1/A
- 6/20/24 - Form 3
- ONCO's page on the SEC website